References
- Kannel W B. Role of blood pressure in cardiovascular morbidity and mortality. Prog Cardiovasc Dis 1974; 7: 5–24
- MacMahon S W, Cutler J A, Furberg C D, Payne G H. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized trials. Prog Cardiovasc Dis 1986; 29: 99–119, (Suppl)
- Editorial. New trials in older hypertensives. Lancet 1991; 338: 1299–1300
- Dahlöf B, Lindholm L, Hansson L, Scherstén B, Ekbom T, Wester P-O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–5
- SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program. JAMA 1991; 265: 3255–64
- MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal result. BMJ 1992; 304: 405–12
- The 1992 report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1993; 153: 154–83
- Workshop-Individualised antihypertensive treatment. Recommendations from a consensus meeting arranged by the Swedish Medical Products Agency. 1990; 3
- The 1993 Guidelines for the management of mild hypertension: memorandum from WHO/ISH meeting. Blood Pressure 1993; 2: 86–100
- The CAPPP group. The Captopril Prevention Project: a prospective intervention trial of angiotensin converting enzyme inhibition in the treatment of hypertension. J Hypertens 1990; 8: 985–990
- Dahlöf B, Hansson L, Lindholm L H. STOP-Hypertension 2-A prospective intervention trial of “newer” versus “older” treatment alternatives in essential hypertension. Blood Pressure 1993; 2: 137–42
- The HOT Study Group. The hypertension optimal treatment study (The HOT-study). Blood Pressure 1993; 2: 62–8
- Godfraind T, Miller R, Wibo M. Calcium antagonism and calcium entry blockade. Pharmacol Rev 1986; 38: 321–416
- Kiowski W, Bolli P, Erne P, Hulthén UL, Müller FB, Bühler FR. Hemodynamic and counterregulatory effects of calcium antagonists in hypertension. J Cardiovasc Pharmacol 1988; 12: 539–43, (Suppl 6)
- Lund-Johansen P, Omvik P. Effect of long-term diltiazem treatment on central haemodynamics and exercise endurance in essential hypertension. Eur Heart J 1990; 11: 543–51
- Leonetti G, Rupoli L, Gradnik R, Zanchetti A. Effects of a low sodium diet on antihypertensive and natriuretic responses to acute administration of nifedipine. J Hypertension 1987; 5: S57–60, (Suppl 4)
- Loutzenhiser R D, Epstein M. Renal hemodynamic effects of calcium antagonists. J Cardiovasc Pharmacol 1988; 12: S48–52, (Suppl 6)
- Scriabine A. Comparative pharmacology of 1.4 dihydropyridines and other Ca++ channel ligands. J Cardiovasc Pharmacol 1987; 9: S3–7, (Suppl 1)
- Chaffman M, Brogden R N. Diltiazem a review of its pharmacological properties and therapeutic efficacy. Drugs 1985; 29: 387–454
- Pool P E, Seagren S C, Salel A F. Effects of diltiazem on serum lipids, exercise performance and blood pressure; randomized, double-blind placebo-controlled evaluation for systemic hypertension. Am J Cardiol 1985; 56: 86H–91
- Pool P E, Massie B M, Venkataraman K. Diltiazem as monotherapy for systemic hypertension: a multicenter, randomized, placebo-controlled trial. Am J Cardiol 1986; 57: 212–7
- Pool P E, Herron J M, Rosenblatt S. Metabolic effects of antihypertensive therapy with a calcium antagonist. Am J Cardiol 1988; 62: 109G–13
- Nikkilä M, Inkovaara J, Heikkinen J, Olsson S-O. Antihypertensive effects of diltiazem in a slow release formulation in patients with mild to moderate essential hypertension. Am J Cardiol 1989; 63: 1227–30
- Andrén L, Höglund P, Dotevall A, Eggertsen R, Svensson A, Olsson S-O, Wadenvik H. Diltiazem in hypertensive patients with type II diabetes mellitus. Am J Cardiol 1988; 62: 114G–120
- Frishman W H, Zawada ET, Jr, Smith L K. Comparison of hydrochlorothiazide and sustained-release diltiazem for mild to moderate systemic hypertension. Am J Cardiol 1987; 59: 615–23
- Massie B, MacCarthy E P, Ramanathan K B. Diltiazem and propranolol in mild to moderate essential hypertension as monotherapy or with hydrochlorothiazide. Ann Intern Med 1987; 107: 150–7
- Weier M R, Josselson J, Giard M I. Sustained-release diltiazem compared with atenolol monotherapy for mild to moderate systemic hypertension. Am J Cardiol 1987; 60: 361–411
- Trimarco B, DeLuca N, Riccardelli B. Diltiazem in the treatment of mild to moderate essential hypertension: comparison with metoprolol in cross-over double-blind trial. J Clin Pharmacol 1984; 24: 218–27
- Hedner T, Thulin T, Gustafsson S, Olsson S-O. For the Swedish Diltiazem-Metoprolol Multicentre Study Group: A comparison of diltiazem and metoprolol in hypertension. Eur J Clin Pharmacol 1990; 39: 427–33
- Thulin T, Hedner T, Gustafsson S, Olsson S-O. Diltiazem compared with metoprolol as add-on-therapies to diuretics in hypertension. J Hum Hypertens 1991; 5: 107–14
- Wolfson P, Abernethy D, DiPette D, Zusman R. Diltiazem and captopril alone or in combination for treatment of mild to moderate systemic hypertension. Am J Cardiol 1988; 62: 103G–8
- Schulte K-L, Meyer-Sabellek W A, Haertenberger A. Antihypertensive and metabolic effects of diltiazem and nifedipine. Hypertension 1986; 8: 859–65
- Pool P E, Seagren S C, Salel A F. Effects of diltiazem on serum lipids, exercise performance and blood pressure: randomized double-blind placebo-controlled evaluation for systemic hypertension. Am J Cardiol 1985; 56: 86H–91
- Pollare T, Lithell H, Mörlin C, Präntare H, Hvarfner A, Ljunghall S. Metabolic effects of diltiazem and atenolol. Results from a randomized, double-blind, study with parallel group. J Hypertens 1989; 7: 551–9
- Hedner T, Samulesson O, Lindholm L. Effects of antihypertensive therapy on glucose tolerance: focus of calcium antagonists. J Intern Med 1991; 229: 101–11, (Suppl 2)
- Dahlöf C, Hedner T, Gustafsson S, Olsson S-O. Effects of diltiazem and metoprolol on blood pressure adverse symptoms and general well-being. Eur J Clin Pharmacol 1991; 40: 453–60
- Bauer J H, Reams G. Short- and long-term effects of calcium entry blockers on the kidney. Am J Cardiol 1987; 59: 66A–71
- Szlachcic J, Tubau J, Massie B M. Diltiazem reduces left ventricular mass but does not change diastolic filling in mild hypertension. J Am Coll Cardiol 1988; 11: 82A
- Moss A J, Oakes Rubison D. Effects of diltiazim on long-term outcome after acute myocardial infarction in patients with and without a history of systemic hypertension. Am J Cardiol 1991; 68: 429–33
- Sunderrajan S, Reams G, Bauer J H. Renal effects of diltiazem in primary hypertension. Hypertension 1986; 8: 238–42
- Sunderrajan S, Reams G, Bauer J H. Long-term renal effects of diltiazem in essential hypertension. Am Heart J 1987; 114: 383–8
- Dahlöf B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients-a metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95–110
- Dahlöf B. Structural cardiovascular changes in essential hypertension. Studies on the effect of antihypertensive therapy. Blood Pressure 1992; 1: 1–75, (Suppl 6)
- Matherson B J, Reda D J, Cushman W C. Single-drug therapy for hypertension in men. New Engl J Med 1993; 328: 914–21
- Hedner T. Calcium antagonists: spectrum of side effects and drug interactions. Acta Pharmacol Toxicol 1986; 58: 119–30, (Suppl II)
- Statistical Abstract of Sweden. Statistics Sweden. 1991
- Isles C G, Walker L M, Beevers D G. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens 1986; 4: 141–56
- Causes of death 1988. Statistics, Sweden 1991
- Hansson L, Hedner T, Dahlöf B. Prospective Randomized Open Blinded Endpoint (PROBE) study: a novel design for intervention trials. Blood Pressure 1992; 1: 113–9